Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.58 which represents a decrease of $-2.15 or -2.13% from the prior close of $100.73. The stock opened at $100.76 and touched ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

In addition, recent price cuts for Januvia under Medicare and a one-time acquisition-related charge impacting operating margins have further pressured Merck's stock performance. Moreover ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Currently, Merck's stock is trading at a price-to-earnings (PE) multiple of 13.6, which is lower than many of its industry peers. In other recent news, Merck & Co. disclosed a 4% increase in third ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...